1. Imai E, Horio M, Watanabe T, et al: Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009;13:621-630
2. Quaggin SE, Kapus A: Scar wars: mapping the fate of epithelial-mesenchymal- myofbroblast transition. Kidney Int 2011;80:41-50
3. Friedman SL, Sheppard D, Duffled JS, et al: Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 2013;5:167sr1
4. Okada T, Nagao T, Matsumoto H, et al: Histological predictors for renal prognosis in diabetic nephropathy in diabetes mellitus type 2 patients with overt proteinuria. Nephrology (Carlton) 2012;17:68-75
5. Shimizu M, Furuichi K, Yokoyama H, et al: Kidney lesions in diabetic patients with normoalbuminuric renal insufficiency. Clin Exp nephrol 2014;18:305-312
6. Mise K, Hoshino J, Ubara Y, et al.: Renal prognosis a long time after renal biopsy on patients with diabetic nephropathy. Nephrol Dial Transplant 2014;29:109-118
7. Humphreys BD, Lin SL, Kobayashi A, et al: Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010;176:85-97
8. Asada N, Takase M, Nakamura J, et al: Dysfunction of fibroblasts of external origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 2011;121:3981-3990
9. Souma T, Yamazaki S, Moriguchi T, et al: Plasticity of renal erythropoietin- producing cells governs fibrosis. J Am Soc Nephrol 2013;24:1599-1616
10. Iwano M, Plietj D, Danoff TM, et al: Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002;110:341-350
11. Zeisberg EM, Potenta SE, Sugimoto H, et al: Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008;19:2282-2287
12. LeBleu VS, Taduri G, O’Connell J, et al: Origin and function of myofibroblasts in kidney fibrosis. Nat Med 2013;19:1047-1053
13. Buchtler S, Grill A, Hofmarksrichter S, et al: Cellular origin and functional relevance of collagen I production in the kidney. J Am Soc Nephol 2018;29:1859- 1873
14. Nangaku M, Eckardt KU: Pathogenesis of renal anemia. Semin Nephrol 2006;26:261-268
15. Koury ST, Bondurant MC, Koury MJ: Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988;71:524-527
16. Obara N, Suzuki N, Kim K, et al: Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood 2008;111:5223-5232
17. Pan X, Suzuki N, Hirano I, et al: Isolation and characterization of renal erythropoietin-producing cells from genetically produced anemia mice. PloS One 2011;6:e25839;10.1371/journal.pone.0025839
18. Yamazaki S, Souma T, Hirano I, et al: A mouse model of adult-onset anaemia due to erythropoietin deficiency. Nat Commun 2013;4:1950;10.1038/ncomms2950
19. Souma T, Nezu M, Nakano D, et al: Erythropoietin synthesis in renal myofibroblasts is restored by activation of hypoxia signaling. J Am Soc Nephrol 2016;27:428-438
20. Suzuki N, Yamamoto M: Roles of renal erythropoietin-producing (REP) cells in the maintenance of systemic oxygen homeostasis. Pflugers Arch 2016;468:3-12
21. Lendahl U, Lee KL, Yang H, et al: Generating specificity and diversity in the transcriptional response to hypoxia. Nat Rev Genet 2009;10:821-832
22. Suzuki N, Gradin K, Poellinger L, et al: Regulation of hypoxia-inducible gene expression after HIF activation. Exp Cell Res 2017;356:182-186
23. Haase VH: Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev 2013;27:41-53
24. Fong GH, Takeda K: Role and regulation of prolyl hydroxylase domain proteins. Cell Death Diff 2008;15:635-641
25. Chen N, Hao C, Peng X, et al: Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. N Engl J Med 2019;381:1001-1010
26. Chen N, Hao C, Liu BC, et al: Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. N Engl J Med 2019;381:1011-1022
27. Suzuki N: Erythropoietin gene expression: developmental-stage specificity, cell- type specificity, and hypoxia inducibility. Tohoku J Exp Med;235:233-240
28. Bachmann S, Le Hir M, Eckardt KU: Co-localization of erythropoietin mRNA and ecto-5’-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 1993;41:335-341
29. Plotkin MD, Goligorsky MS: Mesenchymal cells from adult kidney support angiogenesis and differentiate into multiple interstitial cell types including erythropoietin-producing fibroblasts. Am J Physiol Renal Physiol 2006;291:F902- F912
30. Armulik A, Genové G, Betsholtz C: Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 2011;21:193-215
31. Suzuki N, Matsuo-Tezuka Y, Sasaki Y, et al: Iron attenuates erythropoietin production by decreasing HIF2alpha concentrations in renal interstitial fibroblasts. Kidney Int 2018;94:900-911
32. Forsythe JA, Jiang BH, iyer NV, et al: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-4613
33. Chen C, Pore N, Behrooz A, et al: Regulation of glut1 mRNA by hypoxia- inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 2001;276:9519-9525
34. Chang YT, Yang CC, Pan SY, et al: DNA methyltransferase inhibition restores erythropoietin production in fibrotic murine kidneys. J Clin Invest 2016;126:721- 731
35. Hsieh CL: In vivo activity of murine de novo methyltransferases, Dnmt3a and Dnmt3b. Mol Cell Biol 1999;19:8211-8218
36. Tojo Y, Sekine H, Hirano I, et al: Hypoxia signaling cascade for erythropoietin production in hepatocytes. Mol Cell Biol 2015;35:2658-2572
37. Chevalier RL, Forbes MS, Thornhill BA: Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 2009;75:1145-1152
38. Sousa AM, Liu T, Guevara O, et al: Smooth muscle alpha-actin expression and myofibroblast differentiation by TGFbeta are dependent upon MK2. J Cell Biochem 2007;100:1581-1592
39. Derby I, Skalli O, Gabbiani G: Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab Invest 1990;63:21-29
40. Ignotz RA, Massagué J: Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986;261:4337-4345
41. Sato M, Muragami Y, Saika S, et al: Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003;112:1486-1494
42. Liu Y: Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004;15:1-12
43. Koesters R, Kaissling B, Lehir M, et al: Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am J Pathol 2010;177:632-643
44. Desmoulière A, Geinoz A, Gabbiani F, et al: Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993;122:103-111
45. Verrecchia F, Mauviel A: Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 2002;118:211-215
46. Inman GJ, Nicolás FJ, Callahan JF, et al: SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor- like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002;62:65- 74
47. Chen W, Hill H, Christie A, et al: Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 2016;539:112-117
48. 佐藤浩司、鈴木教郎．腎エリスロポエチン産生細胞と腎線維化．腎臓内科・泌尿器科 2018;7:357-362
49. Hofmann MC, Narisawa S, Hess RA, et al: Immortalization of germ cells and somatic testicular cells using the SV40 large T antigen. Exp Cell Res 1992;201:417-435
50. Kitamura H, Onodera Y, Murakami S, et al: IL-11 contribution to tumorigenesis in an MRF2 addiction cancer model. Oncogene 2017;36:6315-6324
51. Dominici M, Le Blanc K, Mueller I, et al: Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006;8:315-317
52. Bruno S, Chiabotto G, Camussi G: Concise review: different mesenchymal stromal/stem cell populations reside in the adult kidney. Stem Cells Transl Med 2014;3:1451-1455
53. Chen J, Park, HC, Addabbo F, et al: Kidney-derived mesenchymal stem cells contribute to vasculogenesis, angiogenesis and endothelial repair. Kidney Int 2008;74:879-889
54. Wang H, Gomez JA, Klein S, et al: Adult renal mesenchymal stem cell-like cells contribute to juxtaglomerular cell recruitment. J Am Soc Nephrol 2013;24:1263- 1273
55. Jones PA: Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012;13:484-492
56. MacLeod AR, Rouleau J, Szyf M: Regulation of DNA methylation by the Ras signaling pathway. J Biol Chem 2005;270:11327-11337
57. Lund P, Weisshaupt K, Mikeska T, et al: Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation. Oncogene 2006;25:4890-4903
58. Wynn TA, Ramalingam TR: Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012;18:1028-1040
59. Antonelli-Orlidge A, Saunders KB, Smith SR, et al: An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci U S A 1989;86:4544-4548
60. Fan JM, Ng YY, Hill PA, et al: Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 1999;56:1455- 1467
61. Branton MH, Kopp JB: TGF-beta and fibrosis. Microbes Infect 1999;1:1349-1365
62. Disteldorf EM, Krebs CF, Paust HJ, et al:CXCL5 drives neutrophil recruitment in TH17-mediated GN. J Am Soc Nephrol 2015;26:55-66
63. Peng X, Zhang J, Xiao Z, et al: CX3CL1-CX3CR1 interaction increases the population of Ly6C(-)CX3CR1(hi) macrophages contributing to unilateral ureteral obstruction-induced fibrosis. J Immunol 2015;195:2797-2805
64. Ma J, Wang Q, Fei T, et al: MCP-1 mediates TGF-beta-induced angiogenesis by stimulating vascular smooth muscle cell migration. Blood 2007;109:987-994
65. Haider C, Hnat J, Wagner R, et al: Transforming Growth Factor-β and Axl Induce CXCL5 and Neutrophil Recruitment in Hepatocellular Carcinoma. Hepatology 2019;69:222-236
66. Sato K, Kumagai N, Suzuki N: Alteration of the DNA Methylation Signature of Renal Erythropoietin-Producing Cells Governs the Sensitivity to Drugs Targeting the Hypoxia-Response Pathway in Kidney Disease Progression. Front Genet 2019;10:1134;10.3389/fgene.2019.01134
67. Sato K, Hirano I, Sekine H, et al: An immortalized cell line derived from renal erythropoietin-producing (REP) cells demonstrates their potential to transform into myofibroblasts. Sci Rep 2019;9:11254;10.1038/s41598-019-47766-5
68. Jeltsch A: Molecular enzymology of mammalian DNA methyltransferases. Curr Top Microbiol Immunol 2006;301:203-225
69. Hsieh CL: In vivo activity of murine de novo methyltransferases, Dnmt3a and Dnmt3b. Mol Cell Biol 1999;19:8211-8218
70. Asgatay S, Champion C, Marloie G, et al: Synthesis and evaluation of analogues of N-phthaloyl-l-tryptophan (RG108) as inhibitors of DNA methyltransferase 1. J Med Chem 2014;57:421-434
71. Niki T, Rombouts K, De Bleser P, et al: A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology 1999;29:858-867
論文の公開元へ
